Neuroscience Research

Advancing Therapies for Neurological Conditions

Pioneering research into the mechanisms of neurodegeneration — from discovery to clinical translation.

Our Approach

We believe breakthrough science starts with understanding the disease, not just the symptoms.

How We Work

How We Advance Science

We begin with rigorous target identification and validation — mapping the molecular pathways underlying neurodegeneration to find the most promising intervention points.

We design and optimize therapeutic candidates using cutting-edge biology and chemistry, guided by deep mechanistic insight and translational relevance.

We rigorously test candidates in preclinical models that faithfully recapitulate human disease — ensuring every program that advances has a strong scientific rationale.

We move the most promising programs toward clinical development, partnering with leading academic centers and clinical networks to bring new therapies to patients.

Life Sciences

Research Areas

We focus exclusively on neurodegenerative disease — giving our programs depth of scientific expertise and clarity of translational strategy at every stage.

01

Alzheimer's Disease

Targeting amyloid and tau pathology, neuroinflammation, and synaptic dysfunction to develop disease-modifying therapies for Alzheimer's patients.

02

Parkinson's Disease

Investigating alpha-synuclein aggregation, mitochondrial dysfunction, and dopaminergic neuron loss to advance neuroprotective treatments.

03

ALS & Motor Neuron Disease

Exploring RNA metabolism, protein aggregation, and neuroinflammatory mechanisms to develop therapies for ALS and related conditions.

04

Neuroinflammation

Characterizing microglial and astrocyte biology to identify novel anti-inflammatory targets across multiple neurodegenerative indications.

05

Drug Discovery Platform

Leveraging high-throughput screening, structural biology, and AI-driven compound design to accelerate the identification of best-in-class candidates.

06

Biomarkers & Diagnostics

Developing fluid and imaging biomarkers to enable earlier diagnosis, patient stratification, and robust clinical trial endpoints.

Citadel Law Firm team in discussion
The Company

Science Built for Patients

Lifex Biolabs Inc was founded on a simple belief: that patients with neurodegenerative disease deserve better therapies — and that rigorous, focused science is the path to delivering them. We work exclusively on neurodegeneration, bringing depth of expertise and urgency of purpose to every program.

Insights

From the Lab

Alzheimer's Research

Beyond Amyloid: Emerging Targets in Alzheimer's Disease Therapy

Sep 2026

Drug Discovery

How AI Is Accelerating Compound Screening in Neurodegeneration

Aug 2026

Parkinson's Disease

Alpha-Synuclein Aggregation: New Insights and Therapeutic Strategies

Aug 2026

Biomarkers

The Role of Fluid Biomarkers in Early Neurodegenerative Disease Detection

Jul 2026

Neuroinflammation

Microglia in Neurodegeneration: Friend, Foe, or Both?

Jul 2026

ALS Research

RNA-Binding Proteins and ALS: Unlocking a New Class of Targets

Jun 2026

Alzheimer's Research

Beyond Amyloid: Emerging Targets in Alzheimer's Disease Therapy

Sep 2026

Drug Discovery

How AI Is Accelerating Compound Screening in Neurodegeneration

Aug 2026

Parkinson's Disease

Alpha-Synuclein Aggregation: New Insights and Therapeutic Strategies

Aug 2026

Biomarkers

The Role of Fluid Biomarkers in Early Neurodegenerative Disease Detection

Jul 2026

Neuroinflammation

Microglia in Neurodegeneration: Friend, Foe, or Both?

Jul 2026

ALS Research

RNA-Binding Proteins and ALS: Unlocking a New Class of Targets

Jun 2026

Get in Touch

Let's Connect

Whether you're a potential partner, investor, or collaborator — we'd love to hear from you.

By submitting, you agree to our Terms of Use and Privacy Policy